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Summary 
Introduction: Surgeons frequently use surgical antibiotic prophylaxis (SAP), despite limited 
evidence to support its efficacy. Potential adverse events associated with antibiotic use include 
allergic reaction (including anaphylaxis,), Clostridium difficile infection, and selecting for 
resistant bacteria. Surgical site infections (SSI) are very rare in patients undergoing clean 
pediatric urologic procedures. Current guidelines are unclear about the efficacy of surgical 
antibiotic prophylaxis for prevention of SSI in the pediatric population. 
Objective: It was hypothesized that children who received SAP prior to orchiopexy would have 
no reduction in surgical site infection (SSI) risk but an increased risk of antibiotic-associated 
adverse events. 
Methods: A retrospective cohort study was conducted of all males aged between 30 days and 18 
years who underwent an orchiopexy (ICD-9 CM 62.5) in an ambulatory or observation setting 
from 2004-2015 using the Pediatric Health Information System database. Inpatients and those 
with concomitant procedures were excluded. Chi-squared or Fisher’s exact tests were used to 
determine the association between SAP and allergic reaction (defined as a charge for epinephrine 
or ICD-9 diagnosis code for allergic reaction on the date of surgery) and any of the following 
within 30 days: SSI, hospital readmission or any repeat hospital encounter. Mixed effects logistic 
regression was performed, controlling for age, race, and insurance, and clustering of similar 
practice patterns by hospital. 
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Results: A total of 71,767 patients were included: median age was 4.6 years, 61.4% were white, 
and 49.3% had public insurance; 33.5% received SAP. Of these participants, 996/71,767 (1.4%) 
had a perioperative allergic reaction and <0.1% were diagnosed with an SSI. On mixed effects 
logistic regression, those who received SAP had 1.2 times the odds of a perioperative allergic 
reaction compared with those who did not receive SAP (P=0.005). Surgical antibiotic 
prophylaxis was not associated with decreased rates of SSI, lower hospital readmission, nor a 
lower chance of a repeat encounter within 30 days. 
 
Conclusions: In patients undergoing orchiopexy, it was found that SAP did not reduce the risk 
of postoperative SSI, readmissions, or hospital visits. Patients who received SAP had 
significantly increased odds of perioperative allergic reaction. This demonstrated that the risks of 
SAP outweigh the benefits in children undergoing orchiopexy. 
 
Keywords: Surgical site infection; Orchiopexy; Surgical antibiotic prophylaxis 
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Introduction 
Surgical antibiotic prophylaxis (SAP) refers to the use of perioperative antimicrobial agents to 
prevent surgical site infections (SSI). In adult urologic surgery, there is universal support for this 
practice for clean contaminated procedures, contaminated procedures, and dirty procedures. 
American Urological Association (AUA) guidelines recommend the routine use of SAP only in 
clean procedures where associated risk factors are present. European guidelines do not routinely 
recommend their use for clean procedures [1-3]. The variation in appropriate use of SAP in both 
pediatric and adult populations highlights the ambiguity of this topic [4-9]. Decisions about SAP 
use in the pediatric population are complicated by the lack of guidelines.  
Several animal and human studies have demonstrated the benefits of perioperative antibiotic 
prophylaxis [10-13]. However, a recent study of pediatric urology patients demonstrated a very 
low rate of postoperative infection (0.8%) across all wound classifications and surgical sites [14]. 
There was no demonstrable difference in SSI for clean procedures with or without SAP, with 
most SSI occurring in the clean-contaminated surgeries (which universally received SAP). They 
also noted no antibiotic-related adverse events. Given the low rates of SSI (especially with clean 
procedures) and lack of adverse events, the authors suggested focusing upon clean-contaminated 
procedures for future recommendations and studies [14].  
Multiple recent studies of pediatric surgery patients have demonstrated that children who 
received SAP were at a significantly increased risk of receiving epinephrine (a surrogate for 
allergic reaction) and Clostridium difficile (C. difficile) infection compared with those who did 
not receive SAP [4,15]. Macy et al. demonstrated in a retrospective analysis that cephalosporins 
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led to an increased risk of C. difficile infection, anaphylaxis, nephropathy (0.15%) and all-cause 
mortality within 1 day (0.10%) [16]. Wang et al. linked acetaminophen and/or antibiotic 
exposure within the first year of life with certain lifelong diseases, including atopic dermatitis, 
asthma, and allergic rhinitis [17]. Multiple studies have documented cephalosporin cross-
reactivity with other ß-lactam antibiotics, and the ß-lactam family is the most common cause of 
hypersensitivity drug reactions [18,19]. From a population health standpoint, the inappropriate 
use of antibiotics inevitably results in the selection of resistant organisms in the community, 
leading to future morbidity and healthcare costs, especially with respect to methicillin-resistant 
Staphylococcus aureus infections in infants [20-23]. A previous study showed that SAP given 
during pediatric circumcision had no association with SSI, penile reoperation, or hospital visit on 
bivariate analysis, but did lead to an increased risk of allergic reaction or hospital visit on 
multivariate analysis [24].  
 
The current study sought to evaluate, using the Pediatric Health Information System (PHIS) 
database, the effect of SAP at the time of orchiopexy on rates of SSI, readmission, reoperation, 
and antibiotic-associated adverse events. It was hypothesized that children who received SAP 
prior to outpatient orchiopexy would have no reduction in SSI risk, but an increased risk of 
antibiotic-associated adverse events (AAAE).  
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Materials and Methods 
 
Data source 
 
The PHIS is an administrative database that contains inpatient, emergency department, 
ambulatory surgery and observation encounter-level data from over 45 not-for-profit, tertiary 
care pediatric hospitals in the United States. These hospitals are affiliated with the Children’s 
Hospital Association (Overland Park, KS). Data quality and reliability are assured through a joint 
effort between the Children’s Hospital Association and participating hospitals. Portions of the 
data submission and data quality processes for the PHIS database are managed by Truven Health 
Analytics (Ann Arbor, MI). For the purposes of external benchmarking, participating hospitals 
provide discharge/encounter data, including demographics, diagnoses, and procedures. The 
majority of these hospitals also submit resource utilization data (e.g. pharmaceuticals, imaging, 
and laboratory) into PHIS. Data are de-identified at the time of data submission, and subjected to 
a number of reliability and validity checks before being included in the database. The present 
study included data from 43 children’s hospitals.  
 
Study population 
 
A retrospective cohort study was performed of all males aged between 30 days and 18 years who 
underwent an orchiopexy (ICD-9-CM 62.5) with or without herniorraphy (ICD-9-CM 53.0-53.1) 
in an ambulatory or observation setting from January 2004 to December 2015. Patients admitted 
for observation were included to avoid missing patients whose status changed from ambulatory 
to observation due to an intra-operative adverse event such as a perioperative allergic reaction 
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(PAR). Of note, a patient was categorized as having received SAP if a charge was found on the 
day of surgery for an antibiotic. It was assumed that patients with SAP charges received the 
medication. The authors felt confident in the validity of the PHIS pharmacy charges, based on 
the validation study by Chan et al. [25]. Inpatients and those who had length of stay >2 days 
were excluded, as were cases with concurrent procedures, to ensure that the use of SAP was 
associated with orchiopexy alone (Fig. 1). The cohorts that did and did not receive SAP were 
then compared. 
 
Calculation of antibiotic-associated adverse event rates 
 
To characterize the incidence of PAR associated with the administration of SAP, the algorithm 
proposed by Macy et al. was used [26]. All patients with a charge for epinephrine (as a surrogate 
event for an allergic reaction) or an ICD-9 diagnosis code for an allergic reaction on the date of 
surgery were identified (see Appendix 1- ICD9 for allergic reaction). ICD-9 diagnosis codes 
were included for specific types of drug reactions (e.g. dermatitis) as well as drug reactions 
where the specific type of reaction was unknown or not documented.  
 
Thirty-day postoperative antibiotic-associated adverse events were classified as follows: 1) 
perioperative allergic reaction, 2) re-operation, 3) infection within 30 days, 4) day repeat 
encounter for any reason, 5) allergic reaction within 30 days, and 6) hospital admission. Re-
operation was defined as any testicular surgery within 30 days of the orchiopexy (Appendix 2). 
Surgical site infections were defined as any emergency department visit or hospital readmission 
that included either of the following ICD-9 diagnosis codes: 998.51 (infected postoperative 
seroma) or 998.59 (other postoperative infection).  
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Statistical analysis 
Bivariate analyses (Chi-squared and Fisher’s exact test) were performed to determine the 
association between SAP and the four binary perioperative outcome variables:  
1. Perioperative allergic reaction 
2. Re-operation 
3. 30-day SSI rate 
4. 30-day repeat hospital encounter. 
 
Mixed effects logistic regression was then performed, including a random effect for hospital to 
control for clustering of similar practice patterns within institutions. Categorical age, race, 
ethnicity, surgeon type (pediatric surgeon or pediatric urologist), and type of insurance were 
modeled as fixed effects. Each of the four outcome variables were used as dependent variables in 
four different models. The R software package (http://www.r-project.org) and the lme4 library 
were used for mixed effects models (http://cran.r-project.org/package=lme4/). P-values <0.05 
were considered significant. The Institutional Review Board at Indiana University approved this 
study. 
 
Results 
 
A total of 91,919 males who underwent orchiopexy in an ambulatory or observation setting 
during the study period were identified. Of these, 20,243 who underwent concurrent procedures 
(other than hernia repair) were excluded, leaving 71,676 patients for analysis. Of these patients, 
33.5% (23,986) were given SAP and 66.5% (47,690) were not (Fig. 1).  
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Patient characteristics are shown in Table 1. The median age and mean age was 3 years and 4.6 
years, respectively (interquartile range: 1, 8). A total so 49.3% (34,896) had public insurance, 
and 61.0% (43,152) were white. Urologists performed 81.0% of all orchiopexies and 45.2% had 
a concurrent herniorrhaphy. During the procedure (PAR), 1.4% (996 patients) received 
epinephrine or diphenhydramine. During the first 30 postoperative days, 21 soft tissue infections 
(SSI) were identified (<0.1%). 
 
On mixed effects logistic regression, patients who received SAP had a 21% increased risk of a 
PAR compared to those who did not receive SAP (OR 1.21, 95% CI 1.06-1.38, P=0.005). The 
SAP group did not significantly differ in the rate of immediate allergic reaction (during 
encounter) (P=0.438), SSI within 30 days (P=0.385), hospital admission (0.379), or 30-day 
repeat encounter of any kind (P=0.065) (Table 2). 
 
The study then examined how the relative proportion of patients with orchiopexies who received 
SAP changed over time (Fig. 2). This rate increased over the course of the study from 
approximately 20% to 40% of all cases (2004-2015), with an R2 value of 0.36549. Of note, 
during the study period, hospitals joined the PHIS data set. To control for any inter-hospital 
variation, a mixed effects model was used. Thus, for the model-based comparisons, there should 
have not been any confounding hospital variation. 
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Lastly, the study sought to access the degree of inter-hospital variability of SAP use for 
orchiopexy, and this was quite variable, ranging from 3-88% of all orchiopexy cases performed 
at an individual hospital (Fig. 3). 
 
Discussion 
 
Of nearly 71,000 patients undergoing orchiopexy, with or without herniorrhaphy, it was found 
that SAP did not reduce the risk of postoperative surgical site infection, readmission, or repeat 
encounter, but it did significantly increase the risk of PAR. Interestingly, when divided into 
subgroups based upon age, those aged >1 year were just as unlikely to have an infection (95% CI 
crossed 1) (Table 2). 
 
A previous study demonstrated that SAP provided no benefit in pediatric circumcisions, with a 
clear increased risk of adverse events [24]. Previous studies have also suggested the safety of 
eliminating SAP in pediatric hernia repair and orchiopexy; however, relatively small cohorts of 
patients and rare incidence of postoperative surgical site require a large patient cohort to 
determine if a true benefit (or detriment) exists [27]. There is also evidence in the adult literature 
that SAP does not decrease the risk in certain clean procedures, including microsurgical 
varicocelectomy, adrenalectomy, partial nephrectomy, and nephrectomy [28,29]. Other studies 
have demonstrated that topical antibiotic prophylaxis may be more beneficial in adult 
microsurgical varicocelectomies (a clean, adult operation somewhat analogous to pediatric 
orchiopexy) [30]. 
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The current study also discovered an increased risk of an array of adverse events associated with 
SAP. Immediate allergic reaction was found to have an OR of 1.21 in the group given SAP, as 
defined by the use of epinephrine or diphenhydramine or use of any of the previously stated 
ICD-9 diagnosis codes for a drug reaction during the surgical encounter (Appendix 1). 
 
As mentioned in previous studies, a lack of evidence-based guidelines regarding SAP for this 
common procedure has lead to significant variability in the use of SAP. This finding has been 
demonstrated with other clean and clean-contaminated procedures in pediatrics, such as 
circumcision, inguinal hernia repair, hydrocele repair, laparoscopic varicocelectomy, 
hypospadias repair, and endoscopic urological procedures, and spinal procedures [5,31]. Of 
further interest in a study by Chan et al., those using SAP for clean procedures had a higher 
likelihood of using SAP for clean-contaminated procedures. In contrast, those not using SAP for 
clean-contaminated procedures, had a higher likelihood of not using SAP for clean procedures 
either.  
 
The most recent AUA Best Practice Policy Statement recommends SAP for clean-contaminated, 
adult, urologic procedures, and none for clean procedures, unless there are ‘risk factors’ [1]. A 
multi-society guideline also recommends not using SAP for clean pediatric procedures [32]. 
European guidelines have proposed similar recommendations. To address growing concerns of 
drug-resistant strains of bacteria, some have called for a renewed focus on antibiotic stewardship, 
especially in the treatment of children [33,34]. 
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The increasing use of perioperative antibiotics can only be speculated (Fig. 2). It is possible that 
‘minor’ surgery has increasingly been performed at outpatient surgery centers. With an interest 
in efficiency, these centers may lean toward requiring or ‘encouraging’ perioperative antibiotics 
for all surgeries/procedures as a ‘quality measure’; however, this can only be speculated.  
 
This study had some important strengths. By using the PHIS database, it was able to develop a 
large cohort of patients. This allowed relatively rare outcomes to be studied (e.g. immediate 
allergic reactions). By collecting patients throughout the US, and by modeling hospitals as 
random effects, it was able to minimize bias related to particular centers or local patient 
populations. It also studied a relatively common surgical procedure that is relatively commonly 
performed by pediatric urologists (and pediatric surgeons).  
 
There were also notable limitations to this study. The most important were those related to the 
collection of administrative data. With this data set, the study was reliant upon the veracity of the 
43 reporting institutions’ billing and diagnosis documentation. To ensure accuracy, the 
Children’s Hospital Association reviews PHIS data for accuracy on a quarterly basis. As with all 
relatively large data sets, there is a certain limit to the level of granularity. Similarly, the study 
could not capture data related to postoperative course at geographically local primary care 
offices or emergency rooms. Also, given the inclusion of only free-standing, non-for-profit, US 
children’s hospitals, those treated at other institutions were not captured. In addition, it was 
unable to access any outpatient physician records (clinic, telephone, or other) to verify the lack 
of AEs (SSI or otherwise). Theoretically, it could have underestimated the rate of AEs in both 
groups. Given the relatively broad definition of an allergic reaction, it could also have 
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overestimated the true incidence. Epinephrine and diphenhydramine use could have been for a 
number of reasons, including allergy to any other agent received during the surgical encounter. 
Without antigen challenge test results any ‘true’ allergic reaction cannot be confirmed. However, 
this method has been utilized in previous studies [16]. Lastly, given that only those treated 
through a general outpatient setting (no inpatient stays >2 days) and without concurrent surgical 
procedures, the patient population likely excluded a small minority of patients with significant 
medical morbidities. 
 
 
Conclusion 
 
This study found convincing evidence to suggest that SAP for pediatric orchiopexy has no clear 
benefit in the prevention of SSI. In addition, it demonstrated a statistically significant increased 
risk of immediate allergic reaction. Given these findings, the current institution has decided to 
limit antibiotic use for SAP for orchiopexy. Further study in other pediatric urology surgeries is 
invited to further elucidate the benefits and risks associated with SAP for pediatric patients. 
 
Conflict of Interest/Funding: None. 
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Table 1. General demographics. 
 
All With antibiotics Without antibiotics P-value 
N 71,676 23,986 47,690 
Age 
Mean 4.6 4.9 4.5 <0.001 
Median 3 3 3 
Interquartile range 1, 8 1, 8 1, 8 
Race <0.001 
White 43,152 61.0% 14,211 60.5% 28,940 61.3% 
Black 10,034 14.2% 3615 15.4% 6419 13.6% 
Asian 1513 2.1% 513 2.2% 1000 2.1% 
Other 10,711 15.1% 3330 14.2% 7381 15.6% 
Unknown 5310 7.5% 1830 7.8% 3480 7.4% 
Ethnicity <0.001 
Hispanic 13,544 19.2% 4804 20.4% 8740 18.5% 
Non-Hispanic 45,574 64.4% 15,787 67.2% 29,787 63.1% 
Unknown 11,601 16.4% 2908 12.4% 8693 18.4% 
Insurance <0.001 
Commercial 30,504 43.1% 9958 42.4% 20,546 43.5% 
Medicaid 34,896 49.3% 12,165 51.8% 22,731 48.1% 
Other 4354 6.2% 1217 5.2% 3137 6.6% 
Unknown 965 1.4% 159 0.7% 806 1.7% 
Concurrent herniorrhaphy 31,941 45.2% 8998 38.3% 22,943 48.6% <0.001 
Specialty <0.001 
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Urology 57,304 81.0% 20,356 86.6% 36,948 78.2% 
Pediatric Surgery 8431 11.9% 1866 7.9% 6565 13.9% 
Other/unknown 4984 7.0% 1277 5.4% 3707 7.9% 
Allergic reaction 996 1.4% 360 1.5% 636 1.3% 0.07 
Soft tissue infection within 30 days 21 <0.1% 9 <0.1% 12 <0.1% 0.51 
Clostridium difficile infection within 30 days 5 <0.1% 3 <0.1% 2 <0.1% 0.77 
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Table 2. Pre-operative variables and postoperative outcomes. 
 
OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value
Age
<1 - - - - - - - -
1-2 1.04 (0.88-1.22) 0.675784435993079 0.39 (0.13-1.20) 0.101229315502527 0.83 (0.68-1.00) 0.0528943746252005 0.94 (0.87-1.02) 0.148306917248446
3-5 0.73 (0.60-0.89) 0.00223096573819859 0.13 (.020-1.01) 0.050916817002486 0.6 (0.47-0.77) <0.001 0.65 (0.59-0.71) <0.001
6-10 0.44 (0.36-0.55) <0.001 0.31 (0.08-1.16) 0.0812825392345457 0.45 (0.35 -0 .57) <0.001 0.50 (0.46-0.55) <0.001
11-15 0.34 (0.25-0.46) <0.001 0.84 (0.25-2.80) 0.772057414109196 0.42 (0.30-0.57) 7.87251693230038E-080.59 (0.53-0.66) <0.001
16-18 0.43 (0.23-0.79) 0.00630381101928833 Inf 0.994119846465575 1.16 (0.74-1.84) 0.52021215175512 0.90 (0.73-1.12) 0.350868009859617
Race
White - - - - - - - -
Asian 1.24 (0.84-1.83) 0.283992360610874 Inf 0.993816576206511 1.14 (0.71-1.83) 0.59622034042736 0.90 (0.73-1.11) 0.305756234977944
Black 1.30 (1.09-1.55) 0.00401837497919394 0.99 (0.26-3.76) 0.989029627708876 1.12 (0.90-1.39) 0.326239502038143 1.21 (1.11-1.31) <0.001
Other 1.51 (1.27-1.81) <0.001 1.60 (0.51-5.02) 0.417111608360287 0.79 (0.63-1.01) 0.060150837317142 1.30 (1.20-1.42) <0.001
Unknown 0.37 (0.24-0.57) <0.001 1.11 (0.23-5.41) 0.900062657839005 0.76 (0.55-1.05) 0.0981180819377301 0.68 (0.59-0.78) <0.001
Ethnicity
Non-Hispanic - - - - - - - -
Hispanic 0.73 (0.60-0.88) 0.00114094000284029 1.11 (0.34-3.64) 0.860269914885106 1.05 (0.84-1.31) 0.657168878653685 0.94 (0.87-1.03) 0.178742299571877
Unknown 0.7 (0.57-0.87) 0.00112289227800823 1.69 (0.55-5.21) 0.359678958464299 1.19 (0.97-1.47) 0.101378916061915 0.67 (0.61-0.74) <0.001
Insurance
Commercial - - - - - - - -
Medicaid 1.24 (1.06-1.44) 0.00590547870589276 1.77 (0.66-4.76) 0.254511256709037 1.19 (1.00-1.41) 0.0481780203872115 1.35 (1.27-1.45) <0.001
Other 2.41 (1.94-2.99) <0.001 Inf 0.989616967650096 1.28 (0.94-1.74) 0.121285907794099 1.20 (1.06-1.36)0.00524700583110064
Unknown 1.6 (1.07-2.38) 0.0210698507450098 Inf 0.995189542980979 1.00 (0.51-1.94) 0.988984596730348 0.56 (0.40-0.79)0.00107041307263286
Service
Urology - - - - - - - -
Pediatric Surgery 1.07 (0.88-1.31) 0.484690742233349 1.20 (0.35-4.14) 0.776145844702337 1.76 (1.45-2.13) <0.001 1.67 (1.54-1.80) <0.001
Other 2.53 (2.11-3.04) <0.001 0.76 (0.10-5.81) 0.791313289150275 1.41 (1.06-1.87) 0.0178273056891569 1.15 (1.02-1.29) 0.0189459075788829
Antibiotics 1.21 (1.06-1.38) 0.00506233452731544 1.47 (0.61-3.54) 0.385305843327259 1.07 (0.92-1.26) 0.379254922377945 0.94 (0.89-1.00) 0.0651340784105988
Perioperative allergic reaction 30 day SSI Hospital admission 30 day repeat encounter
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Fig. 1. Orchiopexy cohort. 
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Fig. 2. Antibiotic prophylaxis use variation by year. 
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Fig. 3. Antibiotic prophylaxis use variation by hospital. 
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Fig. 4. Antibiotic use variation stratified by hospital size. 
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